Background
Methods
Patient cohort
Statistical analysis
Results
Patient characteristics (n = 9509)
Characteristic | All Patients (%) | Right sided tumour (%) | Left sided tumour (%) |
P value | |
---|---|---|---|---|---|
TNM stage | I | 2104 (22) | 1055 (21) | 1049 (24) | <0.0001 |
II | 3684 (39) | 2059 (41) | 1625 (36) | ||
III | 3721 (39) | 1937 (38) | 1784 (40) | ||
T stage | 1 | 1526 (16) | 715 (14) | 811 (18) | <0.0001 |
2 | 1030 (11) | 558 (11) | 472 (11) | ||
3 | 5075 (53) | 2741 (54) | 2334 (52) | ||
4 | 1868 (20) | 1031 (20) | 837 (19) | ||
N Stage | 0 | 5788 (61) | 3114 (62) | 2674 (60) | 0.06 |
1 | 3065 (32) | 1576 (31) | 1489 (33) | ||
2 | 656 (7) | 361 (7) | 295 (7) | ||
Grade | Well differentiated | 1244 (13) | 635 (13) | 609 (14) | <0.0001 |
Mod. differentiated | 6648 (70) | 3278 (65) | 3370 (76) | ||
Poorly Differentiated | 1617 (17) | 1138 (23) | 479 (11) | ||
Age group | ≤60 | 1925 (20) | 798 (16) | 1127 (25) | <0.0001 |
61–70 | 2423 (25) | 1189 (24) | 1234 (28) | ||
71–80 | 2814 (30) | 1600 (32) | 1214 (27) | ||
>80 | 2347 (25) | 1464 (29) | 883 (20) | ||
Sex | Male | 4913 (52) | 2317 (46) | 2596 (58) | <0.0001 |
Female | 4596 (48) | 2734 (54) | 1862 (42) | ||
Charlson Comorbidity Index | 0 | 5957 (63) | 3027 (60) | 2930 (66) | <0.0001 |
1–2 | 5083 (22) | 1172 (23) | 911 (20) | ||
3–4 | 1023 (11) | 596 (12) | 427 (10) | ||
5 | 446 (5) | 256 (5) | 190 (4) | ||
Adjuvant Chemotherapy | None | 1775 (19) | 955 (46) | 820 (40) | 0.0002 |
Fluorouracil based | 1098 (12) | 553 (27) | 545 (27) | ||
Oxaliplatin doublet | 1233 (13) | 568 (27) | 665 (33) | ||
Unknowna
| 5403 | 2975 | 2428 | ||
Year Diagnosed | 2006–2009 | 5018 (53) | 2644 (52) | 2374 (53) | 0.38 |
2010–2013 | 4491 (47) | 2407 (48) | 2084 (47) | ||
Totals | 9509 | 5051 (53) | 4458 (47) |
5 year all-cause mortality by primary tumour location
Characteristic | Multivariate HR (95% CI) | |
---|---|---|
Sided | Left | 1 |
Right | 0.96 (0.89–1.04) | |
Age | ≤60 | 1 |
61–70 | 1.34 (1.15–1.56) | |
71–80 | 2.23 (1.93–2.56) | |
>80 | 3.97 (3.46–4.56) | |
Grade | Well differentiated | 1 |
Moderately differentiated | 1.22 (1.06–1.39) | |
Poorly Differentiated | 1.87 (1.60–2.17) | |
TNM stage | I | 1 |
II | 1.05 (0.96–1.21) | |
III | 2.00 (1.80–2.24) | |
Sex | Male | 1 |
Female | 0.90 (0.83–0.97) | |
Charlson Comorbidity Index | 0 | 1 |
1–2 | 1.64 (1.49–1.79) | |
3–4 | 1.81 (1.62–2.03) | |
5 | 3.02 (2.63–3.46) | |
Year Diagnosed | 2006–2009 | 1 |
2010–2013 | 0.98 (0.90–1.06) |
Overall Survival HR (95% CI) | Cancer Specific Survival HR (95% CI) | ||||
---|---|---|---|---|---|
Univariate | Multivariatea
| Univariate | Multivariatea
| ||
All Patients | Left Sided |
1
| 1 | 1 |
1
|
Right Sided |
1.20 (1.11–1.29)
| 0.96 (0.89–1.04) | 1.03 (0.91–1.18) |
0.84 (0.73–0.96)
| |
Stage I (n = 2104) | Left Sided | 1 | 1 |
1
|
1
|
Right Sided | 1.03 (0.91–1.18) | 0.84 (0.69–1.01) |
0.66 (0.45–0.95)
|
0.51 (0.35–0.75)
| |
Stage II (n = 3684) | Left Sided | 1 |
1
|
1
|
1
|
Right Sided | 1.002 (0.88–1.14) |
0.85 (0.75–0.98)
|
0.68 (0.52–0.88)
|
0.59 (0.45–0.78)
| |
Stage III (n = 3721) | Left Sided |
1
|
1
|
1
| 1 |
Right Sided |
1.46 (1.31–1.63)
|
1.13 (1.01–1.26)
|
1.43 (1.21–1.69)
| 1.12 (0.94–1.33) |
Cancer specific survival (CSS) primary tumour location
Effect of adjuvant chemotherapy
Characteristic | Stage II (n = 1631) | Stage III (n = 2441) | |
---|---|---|---|
Multivariate | Multivariate | ||
HR (95% CI) | HR (95% CI) | ||
Sided | Left | 1 | 1 |
Right | 0.86 (0.68–1.09) | 1.29 (1.11–1.50) | |
Age | ≤60 | 1 | 1 |
61–70 | 1.90 (1.20–2.99) | 1.21 (0.94–1.54) | |
71–80 | 2.97 (1.92–4.58) | 1.81 (1.43–2.30) | |
>80 | 5.92 (3.82–9.19) | 2.00 (1.54–2.60) | |
Grade | Well/mod differentiated | 1 | 1 |
Poorly Differentiated | 1.43 (1.08–1.90) | 1.49 (1.26–1.75) | |
TNM stage | IIIa | 1 | 1 |
IIIb | 2.20 (1.71–2.82)a
| 1.79 (1.33–2.43) | |
IIIc | - | 3.86 (2.84–5.24) | |
Sex | Male | 1 | 1 |
Female | 0.85 (0.68–1.07) | 0.94 (0.82–1.10) | |
CCI | 0 | 1 | 1 |
1–2 | 1.42 (1.09–1.52) | 1.15 (0.96–1.38) | |
3–4 | 1.60 (1.12–2.28) | 1.20 (0.94–1.53) | |
5 | 2.31 (1.45–3.69) | 1.83 (1.36–2.46) | |
Year Diagnosed | 2006–2009 | 1 | 1 |
2010–2013 | 0.99 (0.79–1.26) | 1.00 (0.86–1.17) | |
Adjuvant Chemotherapy | Nil | 1 | 1 |
Fluorouracil monotherapy | 0.79 (0.51–1.10)b
| 0.48 (0.40–0.57) | |
Oxaliplatin doublet | - | 0.38 (0.27–0.42) |